ArticleJournal of enzyme inhibition and medicinal chemistry2022
Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with
Open access · goldAbstract read
In one paragraph
Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 1 pooled it
6.7field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Efficacy and safety of ramucirumab for gastric or gastro-esophageal junction adenocarcinoma: a systematic review and meta-analysis.European journal of clinical pharmacology · 2024Pooled it
- MTA-NPs induce preferential cytotoxicity, oxidative DNA damage, and mitochondrial apoptosis in human Hep-G2 hepatocellular carcinoma cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Calcium hydroxide nanoparticles-induced oxidative stress and mitochondrial impairment drive genomic instability and programmed cell death in colorectal cancer cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Induction of differential cytotoxicity and ROS-driven severe genomic DNA damage and intrinsic mitochondrial apoptosis by erbium oxide nanoparticles in p53-compromised human NSCLC cells.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- A QbD optimization of a pH-responsive Eudragit S100-chitosan nanoformulation for the co-delivery of pentoxifylline and simvastatin in colorectal cancer therapy.RSC advances · 2026Article
- Yttrium oxide nanoparticles induce potent selective cytotoxicity in HeLa cervical cance cells through ROS-mediated genomic instability and mitochondrial apoptosis.Scientific reports · 2026Article
- Article
- Bioactive glass nanoparticles induce pronounced cytotoxicity in human hepatocellular carcinoma Hep-G2 cells through ROS-mediated genomic instability and mitochondrial apoptosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Bioactive glass nanoparticles induce intrinsic p53-dependent apoptosis and promote genomic instability via ROS overproduction and mitochondrial depolarization in triple-negative breast cancer cells.Scientific reports · 2026Article
- Structure-activity Relationship of Substituted Pyrazoline Derivatives as Small Molecule Tyrosine Kinase Inhibitors.Current medicinal chemistry · 2026Review
- Design, Synthesis, Antimicrobial and Antitumor Activities of Benzo[f]chromene Derivatives: DFT and Molecular Docking.Anti-cancer agents in medicinal chemistry · 2026Article
- Thiazole-driven heterocyclic hybrids as EGFR inhibitors: progress in synthesis and anticancer applications.RSC advances · 2025Review
- Synthesis,Journal of enzyme inhibition and medicinal chemistry · 2025Article
- Unveiling the Cytotoxicity Potential of Nanoemulsion ofPharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Design, Synthesis, and Anticancer Evaluation of New Small-Molecule EGFR Inhibitors Targeting NSCLC and Breast Cancer.International journal of molecular sciences · 2025Article
- Quantum chemical modeling, molecular docking, and ADMET evaluation of imidazole phenothiazine hybrids.Scientific reports · 2025Article
- A Structural Insight Into Two Important ErbB Receptors (EGFR and HER2) and Their Relevance to Non-Small Cell Lung Cancer.Archiv der Pharmazie · 2025Review
- 3,5-Disubstituted pyrazoline as a promising core for anticancer agents: mechanisms of action and therapeutic potentials.Future medicinal chemistry · 2025Review
- Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds.Pharmaceuticals (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 10 institutions in 7 countries.
Esraa A AbdelsalamDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
Amer Ali Abd El-HafeezDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Wagdy M EldehnaDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
Mahmoud A El HassabDepartment of Medicinal Chemistry, Faculty of Pharmacy, King Salman International University (KSIU), South Sinai, Egypt.
Hala Mohamed M MarzoukDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Mahmoud M ElaasserThe Regional Center for Mycology and Biotechnology, Al-Azhar University, Cairo, Egypt.
Nageh A Abou TalebDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
Kamilia M AminDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Hatem A Abdel-AzizDepartment of Applied Organic Chemistry, National Research Centre, Dokki, Giza, Egypt.
Pradipta GhoshDepartment of Cellular and Molecular Medicine, University of California San Diego, La Jolla, CA, USA.
Sherif F HammadDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, Helwan University, Cairo, Egypt.
Helwan University · EGAl-Azhar University · IDBadr University in Cairo · EGCairo University · EGEgypt-Japan University of Science and Technology · EGKing Salman International UniversityNational Cancer Institute · USOrganic Research Centre · GBUniversity of California, San Diego · USVeterans Health Administration · US
Funding
UCSD Cancer Center Training Program in Drug DevelopmentT32CA121938 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Michael Bouvet, Dwayne G. Stupack · 2006 to 2026
$10.3MSpatial Regulation of RGS and G Protein SignalingR01CA100768 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2003 to 2019
$7.4MIntegrators of Metastatic PotentialR01CA238042 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA, LUKER, GARY D · 2019 to 2023
$2.3MModulation of G proteins by Growth FactorsR01CA160911 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GHOSH, PRADIPTA · 2013 to 2017
$1.8MNCI NIH HHS R01 CA100768NCI NIH HHS R01 CA160911NCI NIH HHS R01 CA238042NCI NIH HHS T32 CA121938
Abstract
New series of thiazolyl-pyrazoline derivatives (
Indexed as
Antineoplastic AgentsLung NeoplasmsCell Line, TumorCell ProliferationDrug Screening Assays, AntitumorErbB ReceptorsHumansMolecular Docking SimulationProtein Kinase InhibitorsPyrazolesStructure-Activity RelationshipVascular Endothelial Growth Factor Receptor-2Antineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsPyrazolesVascular Endothelial Growth Factor Receptor-2Anticancerdual kinase inhibitorsEGFR inhibitorsEGFR-mutated NSCLCmolecular dockingVEGFR-2 inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.